@HARMONY-Talks: This is an interview with Prof Anthony Moorman, Newcastle University, HARMONY Partner.
Prof. Moorman is leading the Pediatric Hematologic Malignancies Group. Pediatric Malignancies are the second leading cause of mortality in children in developed countries and hematologic malignancies (HMs) account for 40% of pediatric malignancies. Typical symptoms of pediatric HMs are fatigue and frequent infections. Acute lymphoblastic leukemia (ALL) is the most common HM in children; the other HMs that are studied in HARMONY are rare in children. Read more >>
Watch more interviews we filmed at the 23rd Congerss of the European Hematology Association, which took place in Stockholm, Sweden from 14 - 17 June, 2018.
Click here to visit the HARMONY Youtube channel >> and listen to:
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
